HOME
• effexor xr to wellbutrin xl
• effexor works great cures
• 150 mg effexor
• effexor and libido

depakote and effexor

Risk factors for the development of SSRI- associated hyponatremia including advanced age, female gender, concomitant use depakote and effexor diuretics, low body weight, and lower baseline serum sodium levels have been identified. There have been postmarketing reports of toxic epidermal necrolysis. One case of venlafaxine-induced Stevens-Johnson syndrome has been reported. Although these events occurred during treatment with venlafaxine, causality has not been determined. Ocular Ocular side effects have included abnormal depakote and effexor primarily blurred vision, in approximately 6% of patients.

Go To...

• losing weight on effexor
• effexor and sexdrive
• dosage for effexor
• prevent effexor withdrawal with prozac
• effexor irrational behavior

depakote and effexor

Although these events occurred during treatment with venlafaxine, causality has not depakote and effexor determined. Ocular Ocular side effects have included abnormal vision, primarily blurred vision, in approximately 6% of patients. All reported events are included except those already listed in Table 2 and those events for which a drug cause was remote. Hyponatremia tends to develop within the first few weeks of treatment (range 3 to 120 days) and typically resolves within 2 weeks (range 48 hours to 6 weeks) after therapy has been discontinued with some patients requiring treatment. Although these events occurred during treatment with venlafaxine, causality has not been determined. Hematologic Hematologic side effects have included have frequently included abnormal bleeding (most commonly ecchymosis). Hematologic side effects reported in premarketing Phase 3 trials have included anemia, leukocytosis, leukopenia, lymphadenopathy, thrombocythemia, basophilia, increased bleeding time, cyanosis, eosinophilia, lymphocytosis, multiple myeloma, purpura, and thrombocytopenia. In premarketing trials, treatment with Effexor tablets was associated with a mean final on-therapy increase in total cholesterol of 3 mg/dL. Patients treated with Effexor tablets for at least 3 months in placebo-controlled 12-month extension trials had a mean final on-therapy increase in total depakote and effexor of 9.1 mg/dL compared with a decrease of 7.1 mg/dL among placebo-treated patients. There are not sufficient data with the use of venlafaxine extended-release at doses above 300 mg/day to determine the incidence of sustained increases in blood pressure at these high doses. One study has reported average systolic blood pressure increases of 1.7 depakote and effexor 3.4 mm Hg and average diastolic pressure increases of 0.4 to 2.6 mm depakote and effexor The onset of venlafaxine- associated interstitial pneumonitis has ranged from 1 to 18 months after initial depakote and effexor to the drug and symptomatic improvement occurred after discontinuation of venlafaxine and treatment with corticosteroids. Top More Effexor depakote and effexor depakote and effexor Consumer Information (PDR) Effexor Prescribing Information (FDA) Effexor Consumer Overview Effexor Advanced Consumer (Micromedex) - Includes Dosage Information Effexor MedFacts Consumer Leaflet (Wolters Kluwer) Venlafaxine Prescribing Information (FDA) Effexor XR Prescribing Information (FDA) Effexor XR Extended-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer). Following discontinuation of therapy the amount of REM sleep tends to rebound. Although these events occurred during treatment with venlafaxine, causality has not been determined. A case of dose-related increase of intraocular pressure caused by venlafaxine use depakote and effexor been reported. Metabolic Metabolic side effects have included weight loss (3%). Metabolic side effects reported in premarketing Phase 3 trials have included weight gain, increased alkaline phosphatase, dehydration, hypercholesteremia, hyperglycemia, hyperlipemia, hypoglycemia, hypokalemia, increased SGOT (AST), increased SGPT (ALT), thirst, bilirubinemia, increased BUN, increased creatinine, diabetes mellitus, glycosuria, gout, abnormal healing, hemochromatosis, hypercalcinuria, hyperkalemia, hyperphosphatemia, hyperuricemia, hypocholesteremia, hyponatremia, hypophosphatemia, hypoproteinemia, and uremia. In addition, in premarketing assessment of Effexor XR (the extended release form of venlafaxine), multiple doses were administered to 705 patients in Phase 3 major depressive disorder studies and Effexor was administered to 96 patients. Although these events occurred during treatment with venlafaxine, causality has not been determined. Musculoskeletal Musculoskeletal side effects have included rhabdomyolysis. Musculoskeletal side effects reported in premarketing Phase 3 trials have included arthralgia, arthritis, arthrosis, bone spurs, bursitis, leg cramps, myasthenia, tenosynovitis, bone pain, pathological fracture, muscle cramp, muscle spasms, musculoskeletal stiffness, myopathy, osteoporosis, osteosclerosis, plantar fasciitis, rheumatoid arthritis, depakote and effexor tendon rupture. Although these events occurred during treatment with venlafaxine, causality has not been determined. There have been a minimum of approximately fifteen depakote and effexor of hyponatremia in depakote and effexor at least depakote and effexor was life threatening, including at least one case of recurrent venlafaxine- induced hyponatremia after rechallenge. A recent short-term study (6 weeks) has reported an average weight loss of 2 to 3 pounds in patients treated with venlafaxine. Numerous cases of hyponatremia have been reported following treatment with a selective serotonin reuptake inhibitor (SSRI). The proposed mechanism for depakote and effexor development of hyponatremia involves the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) via release of antidiuretic hormone. Use of venlafaxine has been associated with small but statistically significant increases in total cholesterol, high- density lipoprotein cholesterol and low- density lipoprotein cholesterol. Renal Renal side effects reported in premarketing Phase 3 trials have included kidney calculus, kidney pain, abnormal kidney function, and pyelonephritis. Although these events occurred during treatment with venlafaxine, causality has not been determined. Respiratory Respiratory side effects have frequently included pharyngitis, sinusitis, and yawning. Respiratory side effects reported in premarketing Phase 3 trials have included increased cough, dyspnea, asthma, chest congestion, epistaxis, hyperventilation, laryngismus, laryngitis, pneumonia, voice alteration, atelectasis, hemoptysis, hypoventilation, hypoxia, larynx edema, pleurisy, pulmonary embolus, and sleep apnea. The manufacturer recommends that therapy be discontinued in patients who develop seizures. The depakote and effexor of venlafaxine on pain summation may indicate a potential analgesic effect for clinical neuropathic pain. Nearly all selective serotonin reuptake inhibitors, mixed depakote and effexor reuptake inhibitors, and tricyclic antidepressants cause sleep abnormalities to some extent. Withdrawal symptoms were reported to include brief bursts of dizziness associated with headache, anxiety, irritability, agitation, insomnia, paresthesias, nausea, vomiting, diarrhea, tremor, fatigue, sweating, and worsening of depression (similar to symptoms reported after depakote and effexor from selective serotonin reuptake inhibitors).